Abstract
Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.
Keywords:
cytomegalovirus disease; cytomegalovirus infection; letermovir; therapeutic drug monitoring.
© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
MeSH terms
-
Acetates / administration & dosage*
-
Acetates / pharmacokinetics
-
Acetates / therapeutic use
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / therapeutic use
-
Child, Preschool
-
Compassionate Use Trials
-
Cytomegalovirus Infections / drug therapy*
-
Cytomegalovirus Infections / immunology
-
Cytomegalovirus Infections / virology
-
Cytomegalovirus* / genetics
-
Cytomegalovirus* / isolation & purification
-
DNA, Viral / blood
-
Dose-Response Relationship, Drug
-
Drug Monitoring / methods*
-
Extracorporeal Membrane Oxygenation / adverse effects
-
Fatal Outcome
-
Female
-
Ganciclovir / therapeutic use
-
Hepatitis, Viral, Human / drug therapy
-
Hepatitis, Viral, Human / immunology
-
Humans
-
Immunocompromised Host*
-
Opportunistic Infections / drug therapy
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / virology
-
Polymerase Chain Reaction
-
Quinazolines / administration & dosage*
-
Quinazolines / pharmacokinetics
-
Quinazolines / therapeutic use
-
Treatment Failure
-
Viral Load
Substances
-
Acetates
-
Antiviral Agents
-
DNA, Viral
-
Quinazolines
-
letermovir
-
Ganciclovir